Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Follicular lymphoma tends to grow slowly and often doesn’t cause symptoms in its early stages. Swollen lymph nodes — typically in your armpits, neck, groin, and thighs — are usually the first symptom.

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

The goal of follicular lymphoma treatment is to put your disease into remission. That means your symptoms, and signs doctors look for on scans, diminish or disappear. You can stay in remission for ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Throughout the follicular phase, a single "dominant follicle" develops faster than the rest. This follicle (a fluid-filled sac in your ovary) then releases more estrogen into the body in preparation ...